Compare Ginkgo Bioworks Holdings Inc (DNA) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Five9 Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.02 (market cap $590.53M), while Five9 Inc trades at $24.86 (market cap $1.96B). The key difference: Five9 Inc is far larger — about 3.3× Ginkgo Bioworks Holdings Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | FIVN | |
|---|---|---|
Market Cap | $590.53M | $1.96B |
Sector | Health | Technology |
52-Week High | $16.14 | $29.16 |
52-Week Low | $5.48 | $13.61 |
Enterprise Value | $627.78M | $2.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Five9 (FIVN) trades at $25.81, up 1.53% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong revenue growth, improving profitability, and consistent earnings beats. Recent news includes new executive appointments and AI product launches, alongside ongoing shareholder litigation concerns. Analyst consensus is bullish with a $27.00 price target.
Outlook is positive given earnings momentum and AI-driven growth, but risks include legal overhangs and competitive pressures. The stock offers upside to consensus targets if execution continues, though high valuation multiples require sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
